SynCardia snags $19M for artificial heart

SynCardia raised $19 million to support its Total Artificial Heart.--Courtesy of SynCardia

Arizona's SynCardia Systems has reeled in another $19 million, money the company will use to develop a next-generation Total Artificial Heart.

Athyrium Opportunities Fund kicked in $15 million of the latest round, with previous investors making up the rest. SynCardia already has FDA approval and a CE mark for the original Total Artificial Heart, and the latest cash will help it launch a portable power supply for the device and develop a smaller version of the tech for pediatric patients, CEO Michael Garippa said.

And SynCardia should speed through the regulatory process with the next-gen Total Artificial Heart: The FDA has designated it a Humanitarian Use Device, putting it on the fast track to approval and giving the company the chance to keep up its quick growth rate.

"In 2012, we generated $25 million in revenue and a record-breaking 125 implants at more than 50 SynCardia Certified Centers worldwide," Garippa said in a statement.

The device is indicated as a bridge to transplant for end-stage heart failure patients, but SynCardia plans to ask for the FDA's blessing to use the smaller version as a destination therapy, which could further expand Total Artificial Heart's sales. So far, the device has been implanted in more than 1,100 patients around the world, the company says.

- read SynCardia's announcement

Suggested Articles

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.